T cell injection targeting CD7 chimeric antigen receptor
Sponsors
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Conditions
Anaplastic Large Cell Lymphoma, ALK-negativeAngioimmunoblastic T-cell LymphomaCD7+ T-ALL/LBLCD7-positive Relapsed/Refractory Lymphoid Hematologic MalignanciesCD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/LymphomaEnteropathy-Associated T-Cell LymphomaExtramedullary NK-T-cell Lymphoma, Nasal TypePeripheral T-cell Lymphoma, Nonspecific
Phase 1
CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study
NCT04480788
Start: 2020-11-24End: 2022-08-31Target: 9Updated: 2021-01-06
PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies
NCT05170568
Start: 2021-12-01End: 2024-12-01Target: 22Updated: 2022-11-01
Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
Not yet recruitingNCT07623681
Start: 2026-06-10End: 2028-07-30Target: 12Updated: 2026-06-03
Phase 2
Unknown Phase
CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia
NCT04785833
Start: 2021-03-04End: 2024-02-04Target: 20Updated: 2021-03-08
Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases
Not yet recruitingNCT06871644
Start: 2025-03-18End: 2027-03-31Target: 18Updated: 2025-03-12